bkelly

/Bill Kelly

About Bill Kelly

This author has not yet filled in any details.
So far Bill Kelly has created 971 blog entries.

Yale test can tell whether illness is viral

ccording to the Yale research, a new test that measures Ribonucleic acid or protein molecules in human cells can accurately identify viral infection as a cause of respiratory symptoms. Performed with a simple nasal swab, the test might be a quicker, cheaper way to diagnose respiratory viral illnesses than current methods, said study author Dr. Ellen Foxman, professor of laboratory medicine at the Yale School of Medicine. more

By |January 2nd, 2018|News|0 Comments

Season’s Greetings

By |January 2nd, 2018|News|0 Comments

Branford company wins anthrax testing contract

Branford's Tangen Biosciences has won a federal contract valued at up to $9.4 million to develop an Anthrax diagnostic test. The contract from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) will advance the ability to combat the threat of Anthrax, a potentially deadly bacteria that can cause skin, lung and other diseases, by utilizing Tangen's TangenDx Molecular Diagnostic System. more

By |January 2nd, 2018|News|0 Comments

Quinnipiac U med school opens research lab

Quinnipiac University has opened a dedicated research laboratory at its medical school. The $2 million facility recently was given full certification by the state Department of Public Health and several research projects are underway, said Richard Zeff, Ph.D., professor and chairman of medical sciences and associate dean for scholarship at the university. more

By |January 2nd, 2018|News|0 Comments

BI has option on GSK schizophrenia drugs

Boehringer Ingelheim has lined up an option on the schizophrenia drugs under development at GSK spinout Autifony, including the lead therapy AUT00206. Boehringer agreed to pay up to €627.5 million for global rights to its Kv3 modulators. And after advancing the work on schizophrenia, the partners want to branch out into Fragile X and other CNS ailments. more

By |December 20th, 2017|News|0 Comments

Achillion C3G drug granted orphan status

The FDA has granted orphan drug status to ACH-4471 from Achillion Pharmaceuticals. The drug is used to treat patients with C3 Glomerulopathy (C3G) C3G is a devastating renal disease for which there is no approved therapy. There are estimated to be approximately 4,000 C3G patients in the United States, approximately 4,000 in Europe, and more than 1,000 patients with this devastating disease in Japan. more

By |December 20th, 2017|News|0 Comments

3Q yields $82.1 million in CT venture funding

Connecticut venture funding deals in the third quarter of this year included: Farmington's Bioarray Genetics, which is developing a diagnostic test to detect breast cancer ($5.2 million); Manchester's Woven Orthopedic Technologies, which makes gripping sleeves for orthopedic bone screws ($4.2 million); and West Hartford's ReadyDock, which makes disinfecting stations for cell phones in healthcare and other settings ($1.9 million). The largest Connecticut deal was $50.5 million raised by New Haven biotech Trevi Therapeutics, which is developing a treatment for the skin condition pruritis. more

By |December 20th, 2017|News|0 Comments

Progress on Pfizer/Spark hemophilia therapy

Patients with hemophilia B have seen their symptoms controlled for up to a year with a single dose of a gene therapy developed by Spark Therapeutics, almost entirely eliminating the need for treatment with clotting factors. Results from the phase 1/2 trial of the Pfizer-partnered therapy have been hailed as an “important milestone” for patients with hemophilia B and evidence of a “renaissance” in gene therapy. more

By |December 15th, 2017|News|0 Comments

Good, Coric named 2017 CURE Entrepreneurs of the Year

In a ceremony December 12 at the CURE Annual Holiday Party at Alexion in New Haven, the 2017 CURE Entrepreneur of the Year award was presented to Jennifer Good of Trevi Therapeutics and Dr. Vlad Coric of Biohaven Pharmaceuticals, two biotechnology executives whose work has positively affected bioscience in Connecticut and beyond. Jennifer L. Good is the co-founder of Trevi Therapeutics and serves as a director as well as president and CEO of the company. At Trevi, Ms. Good has successfully raised $100 million, hired a high-caliber team of biotech innovators, and overseen the development of Trevi’s drug candidate from [...]

By |December 15th, 2017|News|0 Comments

Alexion presents results re PNH study

Alexion Pharmaceuticals has presented results from two Phase 1b/2 studies of ALXN1210, the Company’s investigational long-acting C5 complement inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH), a chronic, progressive, debilitating and potentially life-threatening ultra-rare blood disorder characterized by complement-mediated hemolysis. Treatment with ALXN1210 for up to eight months resulted in rapid and sustained reduction of plasma lactate dehydrogenase (LDH) levels, a direct marker of hemolysis, with reductions in mean LDH levels from baseline ranging from 73% to 88% ... more Separately, Alexion has announced  a collaboration and license agreement that enables Alexion to use Halozyme’s ENHANZE drug-delivery technology in the development [...]

By |December 15th, 2017|News|0 Comments